Table 3b.

b. Adverse events ≥ grade 3 occurring >90 days but ≤365 from the start of concurrent treatment (late)

System Organ Class	Term	Grade	Relationship to Treatment	Days from Concurrent RX start
General disorders and administration site conditions	Fatigue	3	Probable	105
Metabolism and nutrition disorders	Hypomagnesemia	4	Possible	183
	Hypokalemia	3	Possible	168
Respiratory, thoracic and mediastinal disorders	Epistaxis*	3	Probable	176
Nervous system disorders	Headache	3	Probable	98
Metabolism and nutrition disorders	Hyponatremia	3	Possible	98
Vascular disorders	Hot flashes	3	Definite	300
General disorders and administration site conditions	Pain	3	Possible	180
Ear and labyrinth disorders	Hearing impaired	3	Probable	333
Metabolism and nutrition disorders	Hypokalemia	4	Probable	136
Nervous system disorders	Neuralgia	3	Possible	126
Infections and infestations	Skin infection	3	Possible	126

^*probably attributable to bevacizumab

Key: RX=treatment